<DOC>
	<DOCNO>NCT00370370</DOCNO>
	<brief_summary>To compare efficacy safety result intravitreal bevacizumab alone bevacizumab + triamcinolone acetonide neovascular AMD .</brief_summary>
	<brief_title>Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone Neovascular AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Cases active neovascular AMD visual acuity 20/400 20/40 History glaucoma ocular hypertension Disciform scar</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Bevacizumab ,</keyword>
	<keyword>Triamcinolone</keyword>
	<keyword>Age-related macular degeneration</keyword>
	<keyword>Choroidal neovascular membrane</keyword>
</DOC>